Drug Database
AM

amphotericin B (Amphomul)

✓ Approved

Bharat Serums and Vaccines Limited · Small Molecule · Small Molecule

What is amphotericin B?

amphotericin B is a small molecule developed by Bharat Serums and Vaccines Limited. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesAmphomul
CompanyBharat Serums and Vaccines Limited
Drug ClassSmall Molecule
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Therapeutic Indications

amphotericin B is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsLeishmaniasis✓ Approved
Infections and infestationsWound infection fungal✓ Approved

Related Research Articles

PubMedChemPlusChem2026-08-31

Synergistic Role of Co0 and Lewis Basic Sites for Transfer Hydrogenation of Substituted Nitroarenes by In Situ Hydrogen Generation.

Sharma Anitya A, Ramchiary Dhanmani D, Sharma Devendra D, Kumar Sahil S et al.

Designing green and efficient methods for synthesizing anilines remains a key challenge in synthetic organic chemistry. Hydrogenation of nitro compounds is one of the most significant and widely employed method for producing functionalized anilines. Consequently, designing catalytic systems capable of hydrogenating nitroarenes under environmentally benign and mild reaction conditions remains a challenge. In this regard, a highly efficient CoAl catalyst has been designed for the hydrogenation of nitroarenes to corresponding amines. Various structural, compositional, and morphological characterizations were done to understand the catalyst's structural and surface properties. The as-synthesized catalyst exhibits excellent activity for the transfer hydrogenation of 1-chloro-4-nitrobenzene to 4-chloroaniline, achieving 98% yield at 60 °C within 1.5 h in ethanol. The developed protocol demonstrated excellent activity for wide range of substituted nitroarenes. Structure-activity relationships of CoAl show that basic sites play a crucial role in the transfer hydrogenation. Furthermore, mechanistic investigations reveal that transfer hydrogenation occurs predominantly via a hydroxylamine-mediated pathway. Moreover, the catalyst maintains good catalytic activity up to four consecutive cycles. This method eliminates the need for high-pressure H2, offering a safe strategy for aromatic amine synthesis. The work demonstrates the potential of earth-abundant, non-noble-metal-based heterogeneous catalysts for hydrogenation reactions under environmentally benign conditions.

PubMedSoft matter2026-08-30

A strategy for preparing porous polymeric micro-/nanomaterials via polymerization-induced self-assembly with process conditions modulated by macromolecular chain transfer agents.

Zhang Furui F, Zhou Xuanxuan X, Zou Yingyi Y, Xu Weishao W et al.

A strategy for the fabrication of porous polymeric micro-/nanomaterials via reversible addition-fragmentation chain transfer (RAFT) polymerization-induced self-assembly (PISA) has been proposed. The process is regulated by tuning the stepwise addition strategy of the macromolecular chain transfer agent (macro-CTA). A systematic study was carried out on three types of polymerization-induced self-assembly (PISA) systems, including redox-initiated and photo-initiated aqueous emulsion polymerization of glycidyl methacrylate (GlyMA), as well as thermally initiated dispersion polymerization of styrene (St) in methanol. All systems were mediated by the same poly(ethylene glycol) methacrylate (PPEGMA) macro-CTA. Experimental results show that all three polymerization-induced self-assembly systems can successfully prepare porous polymer micro-/nanomaterials with regular morphology, tunable pore size, and abundant pores, namely PPEGMA9.1-b-PGlyMAn and PPEGMA9.1-b-PSn. It should be noted that the redox and thermal systems are comprehensively characterized by kinetic and GPC tests, while the photoinitiated system only acts as a supporting demonstration based on TEM images in the supplementary information. Moreover, the process conditions for achieving porous morphologies were explored by adjusting the molar ratio of the macro-CTA added in batches, the time intervals between additions, and the monomer concentration.

PubMedExpert review of vaccines2026-08-30

Narrative review of the clinical safety of MenACYW-TT: a quadrivalent meningococcal vaccine conjugated to tetanus toxoid licensed in the US and abroad.

Syrkina Olga O, Bausch-Jurken Mary M, Delgado Arlette A, Jovanovic Jelena J et al.

Routine meningococcal vaccination campaigns have substantially reduced the burden of invasive meningococcal disease in pediatric individuals, leading to relative increases in burden in older age groups. There is a need for safe, effective meningococcal vaccines that can be used across broad age ranges. MenACYW-TT, a quadrivalent tetanus-toxoid-conjugate meningococcal vaccine indicated for individuals aged ≥6 weeks, is one such option. This narrative review summarizes safety data from industry-sponsored pre- and post-licensure clinical trials of MenACYW-TT, including head-to-head studies with active comparators and coadministration studies with routine pediatric vaccines. In >30 trials involving >17,000 participants, MenACYW-TT had a consistent safety profile across all age groups, from infants to older adults. The most frequent side effects were generally mild or moderate and transient; vaccine-related serious adverse events were rare (<0.1%). The safety of MenACYW-TT was comparable to that of other quadrivalent meningococcal conjugate vaccines. Coadministration did not materially affect the safety of MenACYW-TT or routine pediatric vaccines. Immunization remains an essential preventive strategy against the potentially life-threatening and life-altering consequences of invasive meningococcal disease. The favorable benefit-risk profile of MenACYW-TT reinforces the safety of licensed vaccines and can help to counter vaccine hesitancy.

PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-08-30

CD9+ B Cells Induce T Follicular Helper Cell Apoptosis to Regulate Germinal Center Regression.

Liao Wenjing W, Song Lijuan L, Xu Meiqian M, Liang Tianhao T et al.

Adenoid hypertrophy (AH) is associated with excessive proliferation of germinal center B (GC-B) cells, yet the mechanisms underlying GC regression and termination remain poorly understood. This study used single-cell RNA sequencing (scRNA-seq) to profile the cellular composition of GC-B cells in AH. A unique subset of GC-B cells expressing CD9 was identified through comprehensive scRNA-seq, flow cytometry, and Mass cytometry (CyToF) analyses, with subsequent studies assessing the roles of CD9 and FOXP1 in GC-B cell differentiation and apoptosis pathways. CD9+ B cells were detected throughout GC-B cell development and were regulated by FOXP1. These cells also exhibited activation of cell death-related pathways, particularly during adenoid development. AH samples showed an increase in T follicular helper (Tfh) cells, accompanied by a reduction in CD9+ B cells. In Cd9 knockout mice, CD9 deficiency led to a significant decrease in serum IgG levels. Further analysis revealed that CD9+ B cells promoted Tfh cell apoptosis via pathways such as ALCAM-CD6. CD9+ B cells may regulate GC-B cell regression by inducing Tfh cell apoptosis, and FOXP1 may play a role in their differentiation. These findings clarify mechanisms of GC degeneration and termination, offering potential targets for AH treatment.

PubMedInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2026-08-30

Type 2 Diabetes Reshapes the B-Cell Compartment in Tuberculosis, with Reduction of Transitional B Cells and Expansion of Plasmablasts.

Petrone Linda L, Najafi-Fard Saeid S, Altera Anna Maria Gerarda AMG, Aiello Alessandra A et al.

Type 2 diabetes (T2D) increases the risk of tuberculosis (TB) and TB severity; however, its effects on B-cells in the TB-T2D syndemic are not fully understood. We evaluated by flow cytometry, the distribution of circulating B-cell subsets in patients with TB disease, TB-T2D, subjects with TB infection (TBI), TBI-T2D, healthy controls (HCs), T2D, patients with pulmonary respiratory diseases other than TB (ORDs), and ORD-T2D. Plasma levels of unspecific or PPD-specific IgG and B-cell-related soluble factors were measured by multiplex assays. Total B-cell frequency was similar across groups. TB-T2D patients showed decreased transitional B cells compared to TB, TBI-T2D, HC, and T2D. Transitional B-cell frequency significantly and negatively correlated with HbA1c levels in the TB-T2D group. Moreover, plasmablast frequency was increased in TB-T2D compared to TB, TBI-T2D, and T2D. Unspecific or PPD-specific IgG levels were not modulated by T2D. BAFF levels increased in TB and TB-T2D compared to the other groups, whereas the levels of SDF-1 were decreased in TB and TBI irrespective of T2D, compared to the controls. Overall, T2D reshapes B-cell compartments in TB, reducing potentially anti-inflammatory transitional B-cells and increasing plasmablasts, possibly reinforcing inflammation and impacting B-cell development and humoral immunity in TB-T2D.

PubMedBiochimica et biophysica acta. Molecular basis of disease2026-08-30

Targeting CARM1 impairs DNA damage repair and attenuates B-cell acute lymphoblastic leukemia progression.

Liao Peiyun P, Qiu Yingqi Y, Li Meifang M, Hu Rong R et al.

B-cell acute lymphoblastic leukemia (B-ALL) is a prevalent hematological malignancy, posing difficulties in identifying efficacious treatment strategies for refractory and recurrent patients. Our research revealed that coactivator-associated arginine methyltransferase 1 (CARM1) was highly expressed in B-ALL and associated with unfavorable prognostic outcomes. Down-regulation and inhibition of CARM1 effectively suppressed proliferation and colony formation of B-ALL, while also inducing apoptosis and cell cycle arrest. Mechanistically, inhibition or down-regulation of CARM1 reduced PARP1 level and contributed to double-strand breaks (DSBs) accumulation. Inhibition of CARM1 and PARP1 synergistically supressed B-ALL development. Significantly, the inhibition of CARM1 was found to promote memory differentiation and reduce the exhaustion of CD19-CAR-T cells. Taken together, CARM1 inhibition not only suppressed B-ALL but also enhanced the durability of CAR-T cells against B-ALL, which provides novel insights into the tumor suppression and immune regulation of CARM1 inhibition on cancer therapy.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about amphotericin B